Globus Medical (GMED)
NYSE:GMED
Want to see GMED full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.1Last Year’s EPS
0.86Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, meaningful margin expansion, record non-GAAP EPS, robust cash generation, international and trauma momentum, regulatory wins for patient-specific implants, and upgraded full-year EPS guidance — all indicating solid operational execution and profitable scaling. Primary negatives centered on the Nevro integration (revenue lumpiness and elevated SG&A), a shift in enabling tech deal structures toward leases/rentals that can depress near-term revenue recognition, and some competitive/longer sales cycles in robotics. Overall, the positive performance and durable margin improvements materially outweigh the integration and mix headwinds, while management provided clear plans and targets (mid-70s gross margin long term) that support an optimistic outlook.Company Guidance
Strong Top-line Growth
Q1 revenue of $759.9M, up 27.0% as reported and up 25.5% on a constant currency basis, driven by broad-based strength across businesses.
Significant EPS and Margin Expansion
Fully diluted non-GAAP EPS of $1.12 in Q1, up 64.7% year-over-year; GAAP EPS of $0.90. Adjusted gross profit margin improved to 69.2% (GAAP gross margin 66.4% vs 63.6% prior year). Adjusted EBITDA margin was 32.3%.
Base Business Momentum
Base business revenue of $677.2M, up 13.2% as reported (11.9% constant currency); base musculoskeletal revenue $650.3M, up 12.9% as reported, indicating healthy organic growth across legacy operations.
U.S. Spine Outperformance and Share Gains
U.S. Spine grew ~10% in Q1 (third consecutive quarter of ~10% growth) and the company reported 58 weeks of consecutive growth, with growth driven largely by market share gains across multiple implant categories.
Enabling Technologies and Robotics Traction
Enabling Technologies revenue $26.9M, up ~21% year-over-year; ExcelsiusGPS has supported almost 130,000 robotic procedures to date, supporting continued robotics pull-through and cross-selling opportunities.
International and Trauma Strength
International Spine grew 16.4% as reported and 9.8% constant currency. Trauma business grew 34% year-over-year; neuromonitoring and trauma each grew over 30%, and PRECICE manufacturing now fully supplying the market.
Product and Regulatory Wins
Received two FDA 510(k) clearances early in Q2 for patient-specific Scripps lumbar spacers (7 systems) and Scripps patient-specific rods, positioning the company as the only provider of a complete integrated patient-specific lumbar implant portfolio with its enabling tech.
Balance Sheet and Cash Generation
Cash, cash equivalents, and marketable securities of $799.3M as of 03/31/2026 (up from $629.1M), operating cash flow of $202.4M, and capital expenditures of $39.6M (5.2% of sales). Reiterated $500M buyback program with $390M remaining authorization; company is debt-free after prior debt extinguishment.
Upgraded Full-Year Profit Guidance
Reaffirmed 2026 revenue guidance of $3.18B–$3.22B (implying 8.2%–9.6% growth) and raised non-GAAP fully diluted EPS guidance to $4.70–$4.80 (up from $4.40–$4.50), implying EPS growth of 18.1%–20.6% vs. 2025 driven by margin expansion.
GMED Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GMED Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $85.07 | $77.95 | -8.37% |
Feb 24, 2026 | $91.88 | $96.22 | +4.72% |
Nov 06, 2025 | $61.71 | $83.89 | +35.94% |
Aug 07, 2025 | $54.07 | $58.65 | +8.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Globus Medical (GMED) report earnings?
Globus Medical (GMED) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Globus Medical (GMED) earnings time?
Globus Medical (GMED) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMED EPS forecast?
GMED EPS forecast for the fiscal quarter 2026 (Q2) is 1.1.